Last reviewed · How we verify

Amebic liver abscess — Treatment Landscape & Competitive Intelligence

Amebic liver abscess (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Amebic liver abscess, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tindamax TINIDAZOLE Mission Pharma Nitroimidazole Antimicrobial [EPC] 2004-01-01
Metro I.V. In Plastic Container METRONIDAZOLE Baxter Nitroimidazole Antimicrobial [EPC] 1963-01-01
Metronidazol Metronidazol University of Oslo Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 1 drug in Amebic liver abscess
  2. Mission Pharma · 1 drug in Amebic liver abscess
  3. University of Oslo · 1 drug in Amebic liver abscess

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Amebic liver abscess:

Cite this brief

Drug Landscape (2026). Amebic liver abscess — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/amebic-liver-abscess. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing